Ketamine by mouth - Preliminary review of the literature, including esketamine.
"A systematic review of PO and SL ketamine noted no significant side effects, and no problems with tolerance or substance misuse in any of the studies, which totaled 140 patients who received ketamine up to 3 years in duration…” (Swainson, 2022)
A randomised, open-label, pragmatic pilot comparison of oral and intravenous ketamine in treatment-resistant depression (Kumar, et al, 2024): “In TRD outpatients treated in general hospitals, oral ketamine maybe better accepted and tolerated than iv ketamine.“
Ongoing review of the literature related to safety and efficacy of ketamine by mouth.
Consider Swainson in 2020—